Becton, Dickinson and Company approaches its May 7 Q2 earnings report with a striking split in its positioning data: short sellers have been unwinding aggressively even as options traders edge toward caution.
The short-side retreat is the clearest signal heading into the print. Short interest has collapsed by nearly 32% over the past month, falling from roughly 9.6 million shares in early April to 6.3 million — now representing just 2.2% of the free float. That unwind accelerated through mid-April before stabilising in the final week. Availability in the lending market remains ample, with borrow costs holding at a modest 0.54%, suggesting no squeeze dynamics and little appetite from new short sellers to step in. The ORTEX short score of 32.9 confirms the low-pressure read — well below the midpoint of the 0-100 range.
Options tell a more guarded story. The put/call ratio has climbed to 0.52, running above its 20-day average of 0.43 by roughly 1.4 standard deviations. That is not extreme by historical standards — the 52-week high sits at 1.0 — but the move is notable given the short-side de-risking happening simultaneously. The stock has slipped 5% over the past month to $149.31, with only a faint 0.2% bounce on Friday. Correlated peers have also been under pressure: RMD fell nearly 7% on the week, dropped 11%, and lost 5%. BDX's relative stability, amid broad sector weakness, is itself a mild form of outperformance.
The analyst community has been reassessing the stock since the company's sharp February selloff, when BDX fell 18% in a single session. Goldman Sachs reinstated coverage at Neutral with a $167 target in mid-April, a notably cautious re-entry from a bellwether firm. Piper Sandler trimmed its target to $159 on April 17, also holding Neutral. The Street's consensus sits at hold, with five buys against nine holds and no sell ratings — a configuration that reflects residual respect for the franchise without conviction on near-term upside. Mean targets in the $160–$200 range imply varying degrees of recovery potential from current levels. Bulls point to the spinoff of the Lifesciences business as a catalyst for sharper MedTech focus and projected mid-single-digit growth, with upcoming product launches including the HemoSphere Stream Module and BD Pyxis Pro. Bears flag tariff uncertainty as a live risk to the supply chain and note that debt reduction remains an ongoing drag on capital flexibility.
The February print produced a historically severe one-day loss of 18%. That reaction reset expectations sharply, and the subsequent 32% reduction in short interest suggests many who positioned for further weakness have already moved on. Thursday's report will test whether management's post-spinoff growth narrative has begun to translate into numbers that justify a recovery in the stock — or whether the cautious options positioning reflects a well-founded concern that the earnings bar remains difficult to clear.
See the live data behind this article on ORTEX.
Open BDX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
